SB 825 Prohibits the substitution of anti-epileptic drugs under certain circumstances
Sponsor: Clemens
LR Number: 4647S.01I Fiscal Note: 4647-01N.ORG
Committee: Health, Mental Health, Seniors and Families
Last Action: 2/16/2010 - Hearing Conducted S Health, Mental Health, Seniors and Families Committee Journal Page:
Title: Calendar Position:
Effective Date: August 28, 2010

Full Bill Text | All Actions | Available Summaries | Senate Home Page | List of 2010 Senate Bills

Current Bill Summary

SB 825 - This act requires a pharmacist, pharmacist technician, or pharmacy intern to provide notification to the patient, a family member, other relative, or any other person identified by the patient before interchanging one manufacturer of an anti-epileptic drug for another manufacturer of an anti-epileptic drug in instances where the patient's epilepsy or seizures is currently being controlled on a specific drug, strength, dosage form, and dosing regimen from a specific manufacturer. The prescriber of the medication must also be notified prior to the interchange. This requirement shall not apply to prescriptions dispensed for inpatients of a hospital, a long-term care facility or inpatients of a mental health or residential facility.

This act is similar to SB 1094 (2008).